{"pmid":32312768,"title":"Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.","text":["Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia.","Ann Rheum Dis","Guilpain, Philippe","Le Bihan, Clement","Foulongne, Vincent","Taourel, Patrice","Pansu, Nathalie","Maria, Alexandre Thibault Jacques","Jung, Boris","Larcher, Romaric","Klouche, Kada","Le Moing, Vincent","32312768"],"journal":"Ann Rheum Dis","authors":["Guilpain, Philippe","Le Bihan, Clement","Foulongne, Vincent","Taourel, Patrice","Pansu, Nathalie","Maria, Alexandre Thibault Jacques","Jung, Boris","Larcher, Romaric","Klouche, Kada","Le Moing, Vincent"],"date":"2020-04-22T11:00:00Z","year":2020,"_id":"32312768","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217549","keywords":["communicable diseases, imported","granulomatosis with polyangiitis","hydroxychloroquine","rituximab","systemic vasculitis"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["Rituximab"],"_version_":1664714520057085952,"score":8.518259,"similar":[{"pmid":32241791,"title":"To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.","text":["To consider or not antimalarials as a prophylactic intervention in the SARS-CoV-2 (Covid-19) pandemic.","Ann Rheum Dis","Spinelli, Francesca Romana","Ceccarelli, Fulvia","Di Franco, Manuela","Conti, Fabrizio","32241791"],"journal":"Ann Rheum Dis","authors":["Spinelli, Francesca Romana","Ceccarelli, Fulvia","Di Franco, Manuela","Conti, Fabrizio"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241791","week":"202014|Mar 30 - Apr 05","doi":"10.1136/annrheumdis-2020-217367","keywords":["communicable diseases, imported","hydroxychloroquine","immune system diseases","social work"],"link_comment_for":"32150618","source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664638249294888961,"score":90.783775},{"pmid":32241792,"title":"COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.","text":["COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD.","Ann Rheum Dis","Mihai, Carina","Dobrota, Rucsandra","Schroder, Maria","Garaiman, Alexandru","Jordan, Suzana","Becker, Mike Oliver","Maurer, Britta","Distler, Oliver","32241792"],"journal":"Ann Rheum Dis","authors":["Mihai, Carina","Dobrota, Rucsandra","Schroder, Maria","Garaiman, Alexandru","Jordan, Suzana","Becker, Mike Oliver","Maurer, Britta","Distler, Oliver"],"date":"2020-04-04T11:00:00Z","year":2020,"_id":"32241792","week":"202014|Mar 30 - Apr 05","doi":"10.1136/annrheumdis-2020-217442","keywords":["biological therapy","communicable diseases, imported","cytokines","pulmonary fibrosis","scleroderma, systemic"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["tocilizumab"],"_version_":1664638249386115072,"score":89.77941},{"pmid":32327426,"title":"SLE patients are not immune to covid-19: importance of sending the right message across.","text":["SLE patients are not immune to covid-19: importance of sending the right message across.","Ann Rheum Dis","Goyal, Mohit","32327426"],"journal":"Ann Rheum Dis","authors":["Goyal, Mohit"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32327426","week":"202017|Apr 20 - Apr 26","doi":"10.1136/annrheumdis-2020-217658","keywords":["autoimmune diseases","communicable diseases, imported","epidemiology","hydroxychloroquine","lupus erythematosus, systemic"],"source":"PubMed","topics":["Treatment"],"weight":1,"_version_":1664996914912821248,"score":86.40811},{"pmid":32259878,"title":"A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?","text":["A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine in a patient with COVID-19: Will cases of psoriasis increase after COVID-19 pandemic?","Dermatol Ther","Kutlu, Omer","Metin, Ahmet","32259878"],"journal":"Dermatol Ther","authors":["Kutlu, Omer","Metin, Ahmet"],"date":"2020-04-08T11:00:00Z","year":2020,"_id":"32259878","week":"202015|Apr 06 - Apr 12","doi":"10.1111/dth.13383","keywords":["covid-19","coronavirus","hydroxychloroquine","oseltamivir","psoriasis"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["Hydroxychloroquine","Oseltamivir"],"_version_":1664640769785331713,"score":73.47131},{"pmid":32324284,"title":"COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.","text":["COVID-19 infection and treatment with hydroxychloroquine cause severe haemolysis crisis in a patient with glucose-6-phosphate dehydrogenase deficiency.","Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder caused by red cell enzymatic defects and is associated with haemolytic crisis when patients are exposed to oxidative agents (fava beans, drugs, infections). Hydroxychloroquine is suspected to trigger haemolytic crisis in G6PD deficient patients, and off-label administration of this drug to patients infected with the novel coronavirus (SARS-CoV-2) could cause concern. We report here the first case of severe haemolytic crisis in a patient with G6PD deficiency, initiated by severe COVID-19 infection and hydroxychloroquine use. With worldwide spread of COVID-19, especially in regions with a high prevalence of G6PD deficiency, our case should alert physicians to this possible correlation.","Eur J Haematol","Beauverd, Yan","Adam, Yannick","Assouline, Benjamin","Samii, Kaveh","32324284"],"abstract":["Glucose-6-phosphate dehydrogenase (G6PD) deficiency is an inherited genetic disorder caused by red cell enzymatic defects and is associated with haemolytic crisis when patients are exposed to oxidative agents (fava beans, drugs, infections). Hydroxychloroquine is suspected to trigger haemolytic crisis in G6PD deficient patients, and off-label administration of this drug to patients infected with the novel coronavirus (SARS-CoV-2) could cause concern. We report here the first case of severe haemolytic crisis in a patient with G6PD deficiency, initiated by severe COVID-19 infection and hydroxychloroquine use. With worldwide spread of COVID-19, especially in regions with a high prevalence of G6PD deficiency, our case should alert physicians to this possible correlation."],"journal":"Eur J Haematol","authors":["Beauverd, Yan","Adam, Yannick","Assouline, Benjamin","Samii, Kaveh"],"date":"2020-04-24T11:00:00Z","year":2020,"_id":"32324284","week":"202017|Apr 20 - Apr 26","doi":"10.1111/ejh.13432","keywords":["covid-19","coronavirus","g6pd deficiency","sars-cov-2","haemolysis","hydroxychloroquine"],"source":"PubMed","topics":["Case Report"],"weight":1,"e_drugs":["Hydroxychloroquine"],"_version_":1664895932716548096,"score":68.309654}]}